TriVascular Technologies, Inc. (TRIV)

[dayneyus]

Some interesting projections from Management's last Con. Call

Mike Kramer - TriVascular Technologies Inc. - CFO
On financing, so couple of things -- our first priority is to focus on growth and reaccelerating growth in the short term. Like I said earlier we are tightening our spending and making sure that we -- our incremental resources are focused on revenue generation and driving our growth priorities but we are very focused on managing the burn as well. You should expect that in the near future we'll file a shelf, we think it's just good corporate housekeeping, and we'll look at all of our financing options over the next year or so here, and we'll let you guys know when we have more to say about that.


Chris Chavez - TriVascular Technologies Inc. - President, CEO
...... Everybody is rumored to be working on something smaller. In fact others will state that it's not necessary, but it's interesting that there is a stampede to try and match us. But we are the only system in the world with 14-French system. We have the broadest IFU by far. We are the only system to my knowledge that has made public with the significant number of patients with ID date our ability to preserve and protect the aortic neck.

...So as we step back and look at the big picture we think that with the core we have today 50 plus reps we have the potential for each rep to be at $1.5 million or more[/b], it just makes it a lot of sense for us to consolidate what we have, make sure we get everybody on the right --
...
At the end of the day I think talk is cheap but data matters. What you do in clinical studies matters. What regulatory agencies ultimately approve you to use matters. And that same conference where we were both present, I think the point was made quite in a compelling way that regulatory agencies do not give you an IFU easily, that you have to earn it, you have to be able to support it and I can tell you the facts speak to themselves, our clinical data is compelling. We are the only system that can treat the range of necks -- nobody comes close to what we can do.
I will tell you that there is a lot of spin in the market. That's just part of that being in this business. But I think at the end of the day, people will look at the data. You just have to get it in front of you them, and you've just got to keep beating the drum. And I think when you go to our platform -- first of all Medtronic does not have 14-French outside diameter delivery

Bruce, let me take your first question on Alto. We're making great progress on that. We are -- as I mentioned in my opening comments we expect to be able to do first in man with Alto in the first half of next year and we've got a very well defined regulatory and clinical strategy that we think will get us to the market, we think in fast order.



system.http://files.shareholder.com/downloads/AMDA-2L5UBB/416971497x7935017x828188/8165B612-56BB-4AFF-B365-03CF05357937/TRIV-Transcript-2015-05-05T20_30.pdf